Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Cancer-Critical Genes I: Proto-oncogenes

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

The Extrinsic Apoptotic Pathway

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

NSAIDs for PI3K-altered head and neck cancer: a biomarker-driven therapeutic opportunity.

Cancer biology & medicine·2026

Same author

Constitutively active MEK1 expression driven by the myeloid-selective MRP8 promoter induces epithelial hyperplasia and papilloma formation.

Biochemical and biophysical research communications·2026

Same author

Characterisation of the <i>ARF</i> Gene Family in Salicaceae and Functional Analysis of <i>PeARF18</i> in Heteromorphic Leaf Development of <i>Populus euphratica</i>.

International journal of molecular sciences·2026

Same author

Patient-derived xenograft models of Fanconi anemia-associated head and neck cancer identify personalized therapeutic strategies.

The Journal of clinical investigation·2025

Same author

Loss of Fanconi anemia proteins causes a reliance on lysosomal exocytosis.

Cell death & disease·2025

Same author

Human Papilloma Virus Does Not Fully Inactivate p53 Cellular Activity in HNSCC.

Head & neck·2025

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

Triggering Pyroptosis in Cancer.

Daniel E Johnson^1,2, Zhibin Cui³

¹Department of Otolaryngology-Head and Neck Surgery, University of California at San Francisco, San Francisco, CA 94143, USA.

|March 28, 2025

Summary

This summary is machine-generated.

Pyroptosis, an inflammatory cell death, is a promising cancer therapy. Triggering pyroptosis eliminates cancer cells and enhances anti-tumor immunity, potentially overcoming treatment resistance.

Keywords:

GSDM-E IL-18 IL-1b LPS cancer caspase-1 cell death chemotherapy drugs gasdermin natural products pyroptosis

More Related Videos

LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation

LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation

Published on: May 3, 2024

Examination of Pyroptosis by Flow Cytometry

Examination of Pyroptosis by Flow Cytometry

Published on: May 31, 2024

Related Experiment Videos

Last Updated: Jun 19, 2026

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Evaluation of Caspase Activation to Assess Innate Immune Cell Death

Published on: January 20, 2023

LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation

LPS and ATP-induced Death of PMA-differentiated THP-1 Macrophages and its Validation

Published on: May 3, 2024

Examination of Pyroptosis by Flow Cytometry

Examination of Pyroptosis by Flow Cytometry

Published on: May 31, 2024

Area of Science:

Oncology
Immunology
Cell Biology

Background:

Pyroptosis is an inflammatory programmed cell death pathway involving gasdermin cleavage by caspase-1.
It causes cell membrane damage and releases pro-inflammatory cytokines like IL-1β and IL-18.
Initially observed in immune cells, pyroptosis is now recognized in various cell types, including cancer cells.

Purpose of the Study:

To review mechanisms of canonical and noncanonical pyroptosis in cancer.
To highlight biomolecules that induce pyroptosis in malignancies.
To explore pyroptosis as a cancer treatment strategy and its role in improving the tumor immune microenvironment.

Main Methods:

Literature review of pyroptosis mechanisms in cancer.
Analysis of studies on biomolecules inducing pyroptosis.
Examination of pyroptosis's impact on cancer cell death and immune response.

Main Results:

Pyroptosis offers a novel approach to cancer therapy by directly eliminating cancer cells.
Inducing pyroptosis can remodel the tumor microenvironment, enhancing anti-tumor immunity.
Targeting pyroptotic pathways may sensitize tumors to existing treatments, overcoming resistance.

Conclusions:

Pyroptosis is a potent strategy for cancer treatment, inducing both direct cell death and immune stimulation.
Biomolecules targeting pyroptosis hold promise for developing new anti-cancer therapies.
Further research into pyroptosis pathways could lead to improved treatments for resistant cancers.